Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.
December 17th 2021
David M. O’Malley, MD, explores the use of PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of recurrent/metastatic cervical cancer.
December 3rd 2021
Expert perspective from Anthony B. El-Khoueiry, MD, who reviews the evolving treatment landscape of targeted therapy for advanced/metastatic cholangiocarcinoma.
December 1st 2021
Recommendations for treating advanced renal cell carcinoma with the combination of lenvatinib plus pembrolizumab or lenvatinib plus everolimus, as suggested by Memorial Sloan Kettering Cancer Center’s Chung-Han Lee, MD, PhD, and Kiran Kehoe, RN, BSN, CCRN.
November 1st 2021
Mary F. Mulcahy, MD, breaks down the phase III EPOCH study and explains how it has affected the treatment of colorectal cancer with liver metastasis.
October 19th 2021
Scott T. Tagawa, MD, FACP, reviews the use of 177Lu-PSMA-617 radioligand therapy and clinical implications from the phases 3 VISION trial for patients with metastatic castration-resistant prostate cancer (mCRPC).
October 18th 2021
Karim Fizazi, MD, PhD, provides a discussion on metastatic castrate-resistant prostate cancer and the use of darolutamide for management.
September 30th 2021
Considerations for updated data from the MAIA study of daratumumab plus lenalidomide and dexamethasone, and how they fit into the optimal management of transplant-ineligible newly diagnosed multiple myeloma.
September 24th 2021
Daniel Pollyea, MD, MS, discusses the current treatment options for acute myeloid leukemia.
September 22nd 2021
Naval Daver, MD, explains the current and emerging treatment options for myelodysplastic syndrome.